2fgi: Difference between revisions

New page: left|200px<br /> <applet load="2fgi" size="450" color="white" frame="true" align="right" spinBox="true" caption="2fgi, resolution 2.5Å" /> '''CRYSTAL STRUCTURE OF...
 
No edit summary
Line 1: Line 1:
[[Image:2fgi.gif|left|200px]]<br />
[[Image:2fgi.gif|left|200px]]<br /><applet load="2fgi" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="2fgi" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="2fgi, resolution 2.5&Aring;" />
caption="2fgi, resolution 2.5&Aring;" />
'''CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074'''<br />
'''CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074'''<br />


==Overview==
==Overview==
Angiogenesis, the sprouting of new blood vessels from pre-existing ones, is an essential physiological process in development, yet also plays a, major role in the progression of human diseases such as diabetic, retinopathy, atherosclerosis and cancer. The effects of the most potent, angiogenic factors, vascular endothelial growth factor (VEGF), angiopoietin and fibroblast growth factor (FGF) are mediated through cell, surface receptors that possess intrinsic protein tyrosine kinase activity., In this report, we describe a synthetic compound of the, pyrido[2,3-d]pyrimidine class, designated PD 173074, that selectively, inhibits the tyrosine kinase activities of the FGF and VEGF receptors. We, show that systemic administration of PD 173074 in mice can effectively, block angiogenesis induced by either FGF or VEGF with no apparent, toxicity. To elucidate the determinants of selectivity, we have determined, the crystal structure of PD 173074 in complex with the tyrosine kinase, domain of FGF receptor 1 at 2.5 A resolution. A high degree of surface, complementarity between PD 173074 and the hydrophobic, ATP-binding pocket, of FGF receptor 1 underlies the potency and selectivity of this inhibitor., PD 173074 is thus a promising candidate for a therapeutic angiogenesis, inhibitor to be used in the treatment of cancer and other diseases whose, progression is dependent upon new blood vessel formation.
Angiogenesis, the sprouting of new blood vessels from pre-existing ones, is an essential physiological process in development, yet also plays a major role in the progression of human diseases such as diabetic retinopathy, atherosclerosis and cancer. The effects of the most potent angiogenic factors, vascular endothelial growth factor (VEGF), angiopoietin and fibroblast growth factor (FGF) are mediated through cell surface receptors that possess intrinsic protein tyrosine kinase activity. In this report, we describe a synthetic compound of the pyrido[2,3-d]pyrimidine class, designated PD 173074, that selectively inhibits the tyrosine kinase activities of the FGF and VEGF receptors. We show that systemic administration of PD 173074 in mice can effectively block angiogenesis induced by either FGF or VEGF with no apparent toxicity. To elucidate the determinants of selectivity, we have determined the crystal structure of PD 173074 in complex with the tyrosine kinase domain of FGF receptor 1 at 2.5 A resolution. A high degree of surface complementarity between PD 173074 and the hydrophobic, ATP-binding pocket of FGF receptor 1 underlies the potency and selectivity of this inhibitor. PD 173074 is thus a promising candidate for a therapeutic angiogenesis inhibitor to be used in the treatment of cancer and other diseases whose progression is dependent upon new blood vessel formation.


==Disease==
==Disease==
Line 11: Line 10:


==About this Structure==
==About this Structure==
2FGI is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with PD1 as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Transferase Transferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 and 2.7.10.2 2.7.10.1 and 2.7.10.2] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2FGI OCA].  
2FGI is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=PD1:'>PD1</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Transferase Transferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 and 2.7.10.2 2.7.10.1 and 2.7.10.2] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2FGI OCA].  


==Reference==
==Reference==
Line 18: Line 17:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Transferase]]
[[Category: Transferase]]
[[Category: Eliseenkova, A.V.]]
[[Category: Eliseenkova, A V.]]
[[Category: Froum, S.]]
[[Category: Froum, S.]]
[[Category: Green, D.]]
[[Category: Green, D.]]
[[Category: Hamby, J.M.]]
[[Category: Hamby, J M.]]
[[Category: Hubbard, S.R.]]
[[Category: Hubbard, S R.]]
[[Category: Lu, G.H.]]
[[Category: Lu, G H.]]
[[Category: Mohammadi, M.]]
[[Category: Mohammadi, M.]]
[[Category: Panek, R.L.]]
[[Category: Panek, R L.]]
[[Category: Schlessinger, J.]]
[[Category: Schlessinger, J.]]
[[Category: Schroeder, M.]]
[[Category: Schroeder, M.]]
Line 35: Line 34:
[[Category: tyrosine-protein kinase]]
[[Category: tyrosine-protein kinase]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 22:05:05 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:21:08 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA